DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...

Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 194 % ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

President and COO Jacob Steven Leach, has recently purchased shares of the company, according to a Form 4 filing with the Securities and Exchange Commission. On November 10, 2025, Leach acquired a ...

DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant ...

Kirby McInerney LLP reminds investors who purchased DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities to contact Thomas W. Elrod of Kirby ...